About Cellico Bio
Cellico Bio is a research-stage computational framework for source-grounded protein-fragment review-region prioritization. A review region is a short protein segment flagged for follow-up reading. This page introduces the project and the founder, and links to the public pipeline, evidence map, citations, and contact route.
What Cellico Bio is
Cellico Bio searches protein-fragment space for reproducible, source-grounded review regions worth downstream validation. The system compares short protein segments across changing biological context, then labels each public output by the evidence it can support. Every public artifact is grounded in public sources (UniProt, RCSB PDB, AlphaFold DB, DisProt) or is labelled as schematic.
What Cellico Bio is not
Cellico Bio is research-stage computational triage. The public surface intentionally avoids the following claims:
- No patient intake or patient-readiness claims
- No private health-information intake
- No validated peptide drug candidates
- No outcome claims about aging, germ-line function, or somatic lifespan
- No invented citations, partners, datasets, or outcomes
- Full research-scope statement lives on the disclaimer page
Founder
Byron P. Lee
Founder, Cellico Bio
Byron P. Lee is the founder of Cellico Bio. Background: M.S. Biology (Bioinformatics), Georgia State University; prior work at UCSF in the Peter Walter Lab / HHMI. Active work spans bioinformatics, aging biology, AI-enabled scientific workflows, and community biotech infrastructure. Cellico Bio was founded January 14, 2026.
Where this work is today
Cellico Bio is a research-stage publication companion. The public site shows the workflow, the worked α-synuclein source example, the public-safe figure roadmap, and the evidence-class map for what the framework can and cannot claim. Richer outputs live behind internal review surfaces and require explicit source approval before any public binding.